截止2020年09月28日22時(shí)07分NanoString Technologies Inc.（NSTG）最新價(jià)43.9000，漲跌額0.2100，漲跌幅0.48%，昨收43.6900，今開(kāi)44.6600，最高44.8400，最低43.6800，成交量17420手。

　　NanoString Technologies Inc.（NSTG）2020年01月01日至2020年03月31日Product and service金額（USD）2449.60萬(wàn)，比率92.07%。

　　報(bào)告日期2020年03月31日，年結(jié)日12-31，幣種美元，NanoString Technologies Inc.（NSTG）收入2660.50萬(wàn)，收入增長(zhǎng)-3.91%，毛利1558.80萬(wàn)，毛利增長(zhǎng)-17.87%，歸母凈利潤(rùn)-3862.40萬(wàn)，歸母凈利潤(rùn)增長(zhǎng)-76.38%，基本每股收益-1.04，稀釋每股收益-1.04，銷售毛利率58.59%，銷售凈利率-145.18%。

　　NanoString Technologies Inc.（NSTG）變動(dòng)日期2020年05月05日，變動(dòng)原因定期報(bào)告，已發(fā)行普通股3772.90萬(wàn)，已發(fā)行優(yōu)先股--，公告日期2020年05月08日，已發(fā)行港股--，已發(fā)行國(guó)內(nèi)股--，已發(fā)行海外股3772.90萬(wàn)，已發(fā)行其他股--。

　　NanoString Technologies Inc.（NSTG）主要指標(biāo)（幣種：美元）：截止2020年03月31日NanoString Technologies Inc.（NSTG）市盈率（TTM）-14.4067912701502，市凈率（MRQ）9.14649047197596，每股收益（TTM）-1.52195947763675，每股凈資產(chǎn)3.58170164833974，每股股息（USD）--，周息率--%，收入總額2660.50萬(wàn)，收入總額同比-3.91144177983242%，歸母凈利潤(rùn)-3862.40萬(wàn)，歸母凈利潤(rùn)同比-76.3814046944926%，毛利率58.5904905093028%，凈利率-145.17571884984%，總股本3772.90萬(wàn)，總市值（USD）12.36億。

　　NanoString Technologies Inc.（NSTG）2020年01月01日至2020年03月31日Americas金額（USD）0.20億，比率73.67%。

　　公司介紹： NanoString Technologies, Inc. provides life science tools for translational research and molecular diagnostic products. The company's nCounter Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 2,000 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company collaborates with biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.

　　本站數(shù)據(jù)均為參考數(shù)據(jù)，不具備市場(chǎng)交易依據(jù)。